AtriCure to Participate in the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in the 39th Annual J.P. Morgan Healthcare Conference, scheduled for January 11, 2021, at 10:00 a.m. ET. A live audio webcast of the presentation will be available on the company's website. Additionally, AtriCure will attend one-on-one investor meetings at the Needham Annual Growth Conference on January 14, 2021. The company is known for its innovative technologies, including the FDA-approved Isolator® Synergy™ Ablation System and AtriClip® devices, which are widely used in Afib treatment.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming 39^th Annual J.P. Morgan Healthcare Conference being held virtually.

AtriCure’s management is scheduled to present on Monday, January 11, 2021, at 10:00 a.m. Eastern Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://ir.atricure.com.

AtriCure’s management is also scheduled to participate in one-on-one investor meetings in a virtual setting at the Needham Annual Growth Conference on Thursday, January 14, 2021. Due to the format of this event, no webcast will be available.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator^® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip^® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005105/en/

FAQ

When is AtriCure's presentation at the J.P. Morgan Healthcare Conference?

AtriCure is scheduled to present on January 11, 2021, at 10:00 a.m. Eastern Time.

How can I access AtriCure's presentation at the J.P. Morgan Healthcare Conference?

Interested parties can access the live audio webcast on AtriCure's website in the 'Investors' section.

What other event is AtriCure participating in January 2021?

AtriCure will participate in one-on-one investor meetings at the Needham Annual Growth Conference on January 14, 2021.

What is AtriCure known for?

AtriCure specializes in innovative technologies for treating atrial fibrillation and related conditions, including the FDA-approved Isolator® Synergy™ Ablation System.

What are AtriCure's key products for Afib treatment?

AtriCure's key products include the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System.